Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously
- PMID: 4020387
Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously
Abstract
Muramyl dipeptide and muramyl tripeptide in free form or encapsulated within multilamellar liposomes were injected intravenously into (C57BL/6 X C3H)F1 mice and strain 2 guinea pigs to evaluate their potential acute, subacute, or chronic toxicity. Animals received either single or multiple (X 3, X 4, X 6, X 8) injections. A definite species variation was established with regard to the toxic nature of muramyl peptides. Mice failed to exhibit any changes of a clinical, biochemical, functional, or morphological nature in response to repeated intravenous administrations of high doses of muramyl peptide (free or in liposomes). In contrast, strain 2 guinea pigs were very sensitive to muramyl peptide, regardless of the dose or number of injections, or whether it was given in liposomes or as micelles (free form). Most guinea pigs exhibited vascular pathology reminiscent of the Schwartzman phenomenon. Further toxicity studies of muramyl peptides administered at relevant biological doses are recommended, as well as studies aimed at elucidating the reasons for the species variations.
Similar articles
-
Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice.J Immunol. 1985 Aug;135(2):1372-7. J Immunol. 1985. PMID: 4008926
-
In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.Cancer Res. 1993 Sep 1;53(17):3986-91. Cancer Res. 1993. PMID: 8358727
-
[Effect of GMDP encapsulated into liposomes on metastatic spread of Lewis lung carcinoma].Eksp Onkol. 1988;10(5):40-3. Eksp Onkol. 1988. PMID: 2850149 Russian.
-
Activation of tumoricidal properties in murine macrophages by intravenous injection of muramyl dipeptide encapsulated within liposomes as a treatment for spontaneous metastasis.Prog Clin Biol Res. 1981;75B:257-67. Prog Clin Biol Res. 1981. PMID: 7323097 No abstract available.
-
[Muramyl peptides and their pharmacological properties].Postepy Biochem. 1987;33(2-3):203-29. Postepy Biochem. 1987. PMID: 3330226 Review. Polish. No abstract available.
Cited by
-
Mifamurtide: a review of its use in the treatment of osteosarcoma.Paediatr Drugs. 2010 Jun;12(3):141-53. doi: 10.2165/11204910-000000000-00000. Paediatr Drugs. 2010. PMID: 20481644 Review.
-
Mifamurtide for the treatment of nonmetastatic osteosarcoma.Expert Opin Pharmacother. 2011 Feb;12(2):285-92. doi: 10.1517/14656566.2011.543129. Expert Opin Pharmacother. 2011. PMID: 21226638 Free PMC article. Review.
-
Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs.Pharmaceutics. 2019 Mar 7;11(3):110. doi: 10.3390/pharmaceutics11030110. Pharmaceutics. 2019. PMID: 30866479 Free PMC article. Review.
-
Liposomes as delivery systems in the prevention and treatment of infectious diseases.Pharm World Sci. 1995 Jan 27;17(1):1-11. doi: 10.1007/BF01875551. Pharm World Sci. 1995. PMID: 7719272 Review.
-
Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide in treatment of experimental Klebsiella pneumoniae infection.Infect Immun. 1992 Jan;60(1):95-101. doi: 10.1128/iai.60.1.95-101.1992. Infect Immun. 1992. PMID: 1729201 Free PMC article.